Skip to main content
Map of Intermountain Medical Center and nearby hospitalsIntermountain Health Riverton Hospital, RivertonIntermountain Health Alta View Hospital, SandySt Mark's Hospital, Salt Lake CityAmerican Fork Hospital, American ForkHoly Cross Hospital-Jordan Valley, West JordanPark City Hospital, Park CityLone Peak Hospital, DraperLakeview Hospital, BountifulMountain West Medical Center, TooeleOrem Community Hospital, OremHoly Cross Hospital - Salt Lake, Salt Lake CityPrimary Children's Hospital, Salt Lake CityIntermountain Medical Center
This hospital (dark dot) and the nearest hospitals; dot size shows how many clinicians list each one. Select a dot to open that hospital.

Intermountain Medical Center

Acute Care Hospitals · Voluntary non-profit - Private

5121 South Cottonwood Street
Murray, UT 84107

Call (801) 507-7000

  • Emergency services
  • Medicare overall rating: 5 of 5 stars

At a glance

Clinicians who list this hospital
1,549
Physicians (MD and DO)
1,107
Residents and fellows in training (full-time equivalents, fiscal year 2024)
75
Medical groups
15+

Find a doctor at Intermountain Medical Center →

Quality and patient experience

Medicare overall rating (of 5)
5
Patient survey rating (of 5)
3
Patients who would definitely recommend it (national average 71%)
78%

Compared with the national rate

MeasuresBetterSameWorse
Deaths after treatment170
Safety of care (infections, complications)430
Readmissions and return visits460

Number of Medicare quality measures where this hospital’s rate is statistically better than, the same as (no different from), or worse than the national rate.

What patients said

  • Doctors communicated well 3 of 5 stars
  • Nurses communicated well 3 of 5 stars
  • Explained medicines 2 of 5 stars
  • Discharge information 4 of 5 stars
  • Clean 4 of 5 stars
  • Quiet at night 3 of 5 stars

From 1,383 patient surveys (HCAHPS), period ending 09/30/2025.

Medicare “birthing-friendly” hospital: takes part in a maternity care quality program and follows recommended safety practices.

Source: CMS Care Compare (Hospital General Information; Patient survey HCAHPS). Ratings describe the hospital overall, not individual doctors.

Medical groups whose clinicians work here

Number of each group’s clinicians who list this hospital.

Industry-funded research here

Drug and device companies reported $1,855,455 in research payments to this hospital in 2025 for 62 studies.

  • A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Hea…
    Merck Sharp & Dohme LLC · $194,322
  • An Open-Label Phase 1a,1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Local…
    Merck Sharp & Dohme LLC · $158,400
  • THE ENCIRCLE Trial (#2018-19)
    Edwards Lifesciences Corporation · $121,136
  • A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserv…
    Merck Sharp & Dohme LLC · $118,421
  • A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
    Amgen Inc. · $108,221
  • Edwards Cardioband Tricuspid Valve Reconstruction System Early Feasibility Study 2017-19
    Edwards Lifesciences Corporation · $96,996
  • M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (…
    AbbVie Inc. · $86,788
  • A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
    Celgene Corporation · $84,428
  • Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
    AbbVie Inc. · $77,607 · Active, not recruiting
  • A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
    Sumitomo Pharma America, Inc. · $56,204 · Recruiting
  • M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma
    AbbVie Inc. · $55,686
  • Shortcut Pivotal Study
    Pi-cardia, Inc. · $52,600

From CMS Open Payments research payments to this hospital as a teaching hospital. Payments to affiliated universities or research foundations are reported under those names. All industry-funded trials →

Other hospitals in the same county

Sources: CMS Hospital General Information and Doctors and Clinicians Facility Affiliation (Care Compare), CMS certification number 460010. Counts are clinicians who list this hospital with Medicare; they include part-time and visiting clinicians and aren’t staff totals. Residents and beds are from the hospital’s Medicare cost report. Ratings are Medicare’s, not ours.